Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c)

As of December 31, 2025, cash and cash equivalents were $57.1M, compared to $65.7M as of September 30, 2025. The company believes its cash and cash equivalents as of December 31, 2025, will be sufficient to fund operational expenses and capital requirements into the fourth quarter of 2026. “We have initiated a process to explore a range of alternatives available to the Company to maximize stockholder value,” said Daniel Hicklin, president and CEO of Werewolf. “Such measures may include, among other options, a sale of the Company, a business combination or merger, a sale of assets, licensing or collaboration arrangements, or other strategic transactions. In addition to our clinical-stage candidates and our named earlier-stage candidates, our INDUKINE and INDUCER platforms provide exciting opportunities to apply our differentiated masking and protease linker technology in multiple additional modalities.”